Cannabis in the treatment of fibromyalgia: systematic review

Introduction and clinical context

The study Cannabis in the treatment of fibromyalgia: systematic review (PMC · 2023) is part of the scientific research on the use of cannabinoids in fibromyalgia and migraine.

In fibromyalgia — a chronic widespread pain syndrome with fatigue and sleep disturbances — and in migraine, cannabinoids are investigated for their analgesic potential and their modulation of pain perception. Clinical trials with THC-rich oil and with vaporized cannabis suggest an improvement in symptoms and quality of life in some patients, although the evidence is still limited and the response varies. Use should be individualized and monitored.

Understanding what science shows about the use of cannabinoids in fibromyalgia and migraine helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. Review of 564 patients: evidence of short-term pain reduction with cannabinoids in fibromyalgia. As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

In fibromyalgia and migraine, cannabinoids modulate the perception and central processing of pain through the endocannabinoid system, with the hypothesis of a clinical endocannabinoid deficiency in these centralized-pain conditions. The most common adverse effects are dizziness, drowsiness and dry mouth, and THC can have a psychoactive effect. Attention is recommended to interactions with other analgesics and psychotropics. Gradual titration and follow-up help balance symptomatic relief and tolerability, with a preference for starting at low doses.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PMC · 2023). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis help in fibromyalgia?

There are trials suggesting an improvement in symptoms and quality of life; the evidence is limited and use is individualized.

Does cannabis work for migraine?

A trial with vaporized cannabis outperformed placebo in acute relief; the research is still early.